Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6343224 | 0.78 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2HTTMAPTKDM4E | |
| SCHEMBL4001716 | 0.76 | ALDH1A1 (0.75) | ALDH1A1SMN1; SMN2HTTMAPTPOLB | |
| SCHEMBL23057067 | 0.75 | ALDH1A1 (0.66) | ALDH1A1MAPTNPSR1KDM4EPOLB | |
| SCHEMBL6407500 | 0.75 | L3MBTL1 (0.41) | ALDH1A1SMN1; SMN2MAPTNPSR1KDM4E | |
| SCHEMBL4005240 | 0.74 | GAA (0.71) | ALDH1A1SMN1; SMN2HTTMAPTPOLB | |
| SCHEMBL6410153 | 0.73 | KDM4E (0.43) | ALDH1A1SMN1; SMN2HTTMAPTNPSR1 | |
| SCHEMBL1946932 | 0.73 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2HTTMAPTKDM4E | |
| SCHEMBL4735003 | 0.71 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2HTTMAPTNPSR1 | |
| SCHEMBL6939799 | 0.71 | P2RX7 (0.59) | ALDH1A1SMN1; SMN2HTTMAPTNPSR1 | |
| SCHEMBL6343152 | 0.71 | KMT2A (0.55) | ALDH1A1SMN1; SMN2HTTMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050137248-A1 | Substituted cyclic amine metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2005-06-23 | — | — | US | claimed |
| US-20030191163-A1 | Substituted cyclic amine metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-10-09 | — | — | US | claimed |
| US-20030105153-A1 | Substituted cyclic amine metalloprotease inhibitors | PROCTER & GAMBLE COMPANY, THE | 2003-06-05 | — | — | US | claimed |
| US-6417219-B1 | ENZYME INHIBITORS AND OSTEOARTHRITIS | THE PROCTOR & GAMBLE COMPANY | 2002-07-09 | — | — | US | claimed |
| US-20020072517-A1 | Substituted cyclic amine metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2002-06-13 | — | — | US | claimed |
| US-20020061877-A1 | Substituted cyclic amine metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2002-05-23 | — | — | US | claimed |
| US-20050272745-A1 | Novel piperidine and piperazine derivatives | ASTRAZENECA AB | 2005-12-08 | — | — | US | disclosed |
| US-6969713-B2 | Piperidine and piperazine acetamide derivatives | ASTRAZENECA AB (SE) | 2005-11-29 | — | — | US | disclosed |
| EP-1242427-B1 | NOVEL PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2003-08-13 | — | — | EP | disclosed |
| US-20030013721-A1 | Novel piperidine and piperazine derivatives | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | disclosed |
| EP-1242427-A1 | NOVEL PIPERIDINE AND PIPERAZINE DERIVATIVES | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001046200-A1 | NOVEL PIPERIDINE AND PIPERAZINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272745-A1 | Novel piperidine and piperazine derivatives | CYP3A5, IL5, ABCC5 | ALDH1A1 187/4885SMN1; SMN2 3028/4885HTT 2638/4885 |
| US-20020061877-A1 | Substituted cyclic amine metalloprotease inhibitors | CMA1, ADAM17, MMP25 | ALDH1A1 314/4885SMN1; SMN2 1518/4885HTT 3966/4885 |
| US-20030013721-A1 | Novel piperidine and piperazine derivatives | IL5, VIP, EP300 | ALDH1A1 68/4885SMN1; SMN2 2063/4885HTT 2520/4885 |
| US-20030191163-A1 | Substituted cyclic amine metalloprotease inhibitors | CMA1, ADAM17, MMP25 | ALDH1A1 314/4885SMN1; SMN2 1518/4885HTT 3966/4885 |
| US-20050137248-A1 | Substituted cyclic amine metalloprotease inhibitors | CMA1, ADAM17, MMP25 | ALDH1A1 538/4885SMN1; SMN2 1619/4885HTT 3701/4885 |
| US-20020072517-A1 | Substituted cyclic amine metalloprotease inhibitors | CMA1, ADAM17, MMP25 | ALDH1A1 314/4885SMN1; SMN2 1518/4885HTT 3966/4885 |
| US-20030105153-A1 | Substituted cyclic amine metalloprotease inhibitors | CMA1, ADAM17, MMP25 | ALDH1A1 314/4885SMN1; SMN2 1518/4885HTT 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.